Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...
2don MSN
European markets opened higher on Tuesday, in a shortened trading session for Christmas Eve. At the opening bell, the ...
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage ...
Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...
Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising ...
Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...
Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results